Metformin in Safety and Efficacy in Gouty Patients
the Impact of Metformin Use on Clinical Outcomes in Gouty Patients
Mostafa Bahaa
70 participants
Apr 20, 2025
INTERVENTIONAL
Conditions
Summary
The most frequent crystal arthropathy is gout, which is also the most prevalent cause of inflammatory arthritis. Gouty Patients frequently have excruciating pain and swelling in their joints. Gout is linked to decreased health-related quality of life and functional disability. Gout and its associated diseases have been shown to have a significant impact on patients mortality and morbidities. Metformin, a biguanide, is used to manage diabetes by reducing insulin resistance and preventing comorbidities such as cerebrovascular and coronary artery disease, as well as providing renal protection to diabetic nephropathy patients
Eligibility
Inclusion Criteria1
- Gouty patients clinically diagnosed as gouty arthritis based on the American College of Rheumatology/European League Against Rheumatism criteria of gout.
Exclusion Criteria5
- Systemic disorders such as cardiovascular, neurological, coronary artery disease.
- Hypertension, hyperlipidemia, diabetes mellitus, active infections.
- Other inflammatory or autoimmune diseases.
- Patients on biologics,
- Cases with hypersensitivity to metformin and those with impaired liver and kidney functions.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Placebo will have the same look of metformin
Metformin, a biguanide, is used to manage diabetes by reducing insulin resistance and preventing comorbidities such as cerebrovascular and coronary artery disease, as well as providing renal protection to diabetic nephropathy patients
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06924658